 |
|
Waiting Time in Prostate Cancer
Alfred I. Neugut, MD, PhD;
Victor R. Grann, MD, MPH
JAMA. 2004;291:2757-2758.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
The study from Johansson and colleagues1 published in this issue of THE JOURNAL illustrates why oncologists often substitute the jargon of survival rates to sidestep using the magic word cure, which is really what's on every patient's mind.1 In this well-conducted investigation, the researchers complete more than 2 decades of follow-up for a cohort of more than 200 Swedish men with early-stage prostate cancer from before the prostate-specific antigen (PSA) era who were treated with watchful waiting. Earlier reports by Johansson et al documented the relatively high rates of recurrence and mortality for those with high-grade tumors and the relatively lower rates among those with low-grade tumors, extending up to about 15 years of follow-up.2-8 In the current article, the authors extend their follow-up to more than 20 years and find a surprising acceleration in the recurrence and mortality . . . [Full Text of this Article]
Author Affiliations: Department of Medicine and Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, and the Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Natural History of Early, Localized Prostate Cancer
Jan-Erik Johansson, Ove Andrén, Swen-Olof Andersson, Paul W. Dickman, Lars Holmberg, Anders Magnuson, and Hans-Olov Adami
JAMA. 2004;291(22):2713-2719.
ABSTRACT
| FULL TEXT
|
